HIV and its treatment
HIV disease progression occurs when the virus replicates and infects new cells. HIV primarily targets CD4 T-cells, which direct the body’s immune response. As HIV infects and kills more CD4 cells, the body is less able to defend itself against viruses, bacteria, and other pathogens. This process is discussed in more detail in How the immune system works.
Disrupting HIV replication prevents the virus from infecting new cells and allows for CD4 cell recovery. The virus has a complex life-cycle that involves entering a cell, inserting and copying viral genetic material, producing new viral proteins, and assembling these proteins into new viral particles (virions) that can go on to infect other cells.
Because the HIV life-cycle has so many steps, drugs can disrupt the virus in many different ways. The most effective regimens combine drugs from different classes, thereby attacking HIV from multiple angles. Doing so reduces the ability of the virus to develop drug resistance.
While today’s highly active antiretroviral therapy (HAART) regimens can dramatically reduce HIV replication, some antiretroviral drugs also interfere with the normal workings of human cells, and thus can cause a variety of side-effects.
latest aidsmap news
- Slow progress to expand rountine HIV testing in the US
- Concerns over miscarriage of justice after first UK conviction for transmission of hepatitis B
- High rate of death amongst patients with HIV diagnosed late
- CD4 cell count increases sustained up to five years in developing-world treatment programmes
- Raltegravir may have role in PEP if exposure involves drug-resistant HIV
- Excellent outcomes from five years of antiretroviral use in Botswana
- Study explores verbal and non-verbal communication in unprotected sex between men
- IL-2 provides quick ‘AIDS rescue’, but effect does not always last
- Once-a-day etravirine should work as first-line treatment
- Second-line combinations fail twice as often as first-line ones in the first year
